Nakanishi, Tomoko http://orcid.org/0000-0001-9510-5646
Willett, Julian http://orcid.org/0000-0002-8103-0329
Farjoun, Yossi
Allen, Richard J.
Guillen-Guio, Beatriz
Adra, Darin
Zhou, Sirui
Richards, J. Brent http://orcid.org/0000-0002-3746-9086
Funding for this research was provided by:
Gouvernement du Canada | Canadian Institutes of Health Research (365825; 409511, 100558, 169303, 476575)
Canada Foundation for Innovation
Cancer Research UK
Public Health Agency of Canada
Fonds de Recherche du Québec - Santé
MEXT | Japan Society for the Promotion of Science (22KJ1190, 22J30004, 23H02917)
Wellcome Trust (221680/Z/20/Z)
Article History
Received: 5 October 2022
Accepted: 21 September 2023
First Online: 4 October 2023
Competing interests
: T.N. has received speaking fee from Boehringer Ingelheim for the talks unrelated to this research. J.B.R.’s institution has received investigator-initiated grant funding from Eli Lilly, GlaxoSmithKline and Biogen for projects unrelated to this research. J.B.R. is the CEO of 5 Prime Sciences (ExternalRef removed), which provides research services for biotech, pharma and venture capital companies for projects unrelated to this research. Y.F. is an employee of 5 Prime Sciences. All other authors declare no competing interests.